

Synthesis and evaluation of some novel 1,2,4-triazole derivatives for antimicrobial, antitubercular and anti-inflammatory activities

Shashikant Pattan*^a, Priyanka Gadhave^a, Vishal Tambe^a, Santosh Dengale^a, Deepak Thakur^a,
S V Hiremath^b, R V Shete^c & Pravin Deotarse^d

^aDepartment of Pharmaceutical Chemistry, Pravara Rural College of Pharmacy, Pravaranagar 413 736, India

^bDepartment of Pharmacology, J N Medical College, KLE University, Belgaum 590 010, India

^cDepartment of Pharmacology, R. D. S. College of Pharmacy, Bor 412 206, India

^dLupin Bioresearch Center, Pashan, Pune 411 021, India

E-mail: shashipattan@yahoo.com

Received 10 August 2010; accepted (revised) 10 October 2011

A series of 1,2,4-triazole derivatives have been synthesized and evaluated for antimicrobial, antitubercular and anti-inflammatory activities. The newly synthesized compounds have been characterized by IR, ¹H NMR and CHN analysis. All the compounds have shown promising antimicrobial, antitubercular and anti-inflammatory activities when compared with standard drug Norfloxacin, Griseofulvin, Streptomycin and Diclofenac sodium respectively.

Keywords: Antimicrobial, anti-inflammatory, antitubercular activity, CHN analysis, 1,2,4-triazole

Tuberculosis (abbreviated as TB for Tubercle Bacillus) is a common and deadly infectious disease that is caused by mycobacteria, primarily TB. Tuberculosis most commonly affects the lungs (as pulmonary TB) but can also affect the central nervous system, the lymphatic system, the circulatory system, the urinogenital, bones, joints and even the skin. Other mycobacteria such as *Mycobacterium bovis*, *Mycobacterium africanum*, *Mycobacterium canetti* and *Mycobacterium microti* can also cause tuberculosis, but these species do not usually infect healthy adults¹.

There are two fundamental types of inflammation²

- (i) Acute inflammation and
- (ii) Chronic inflammation.

Various derivatives of 1,2,4-triazoles possess a wide spectrum of activity ranging from antibacterial, antifungal, antiinflammatory, anticonvulsant, antineoplastic, antimalarial, antiviral, anticancer, anti-TB, and antiproliferative³.

It is well known that the mercapto group attached to heterocyclic nucleus enhances the fungicidal activity⁴.


Results and Discussion

Eight new derivatives of triazole were synthesized. The synthesized compounds were subjected to antimicrobial, antitubercular and anti-inflammatory activity studies. Compound **5b**, **5d**, **5f**, **5g** and **5h** have shown promising antibacterial and antifungal activity. Compounds **5e** and **5g** have shown promising antitubercular activity at 25 µg/mL, 50 µg/mL and 100 µg/mL concentration. Compounds **5b** and **5d** have shown promising anti-inflammatory activity.

The compounds were incorporated with SO₂NH₂ in **5b**, **5d**, **5f**, **5g** and **5h**. The compounds were incorporated with isoniazide, hence enhanced anti-tubercular activity was observed in compound **5e** and **5g**. Compounds **5b** and **5d** were incorporated with Diclofenac and mefenamic acid hence enhanced anti-inflammatory activity was observed in these compounds (**Scheme I**, **Table I**). With still further molecular modification and manipulation these compounds can be expected to be promising therapeutic agents in the future.

Antimicrobial activity^{5,6}

Antimicrobial activity was carried out by cup-plate agar diffusion method using nutrient agar. The



Scheme I

Table I — Analytical data of the synthesized compounds

Compd	Mol. Formula	Mol. Wt	m.p. (°C)	Yield (%)	R _f Value	Calcd % (Found)		
						C	H	N
5a	C ₁₈ H ₂₀ N ₄ S	471	108	78	0.56	69.57 (69.40)	6.7 6.06	16.23 16.15)
5b	C ₁₁ H ₁₃ N ₃ S	522	110	92	0.65	56.84	5.04	11.05
5c	C ₂₁ H ₁₈ N ₆ OS	402	96	68	0.56	65.85 (65.70)	6.01 65.08	16.69 16.50)
5d	C ₂₁ H ₂₁ N ₆ OS	453	102	69	0.52	64.84	5.44	18.90
5e	C ₁₆ H ₁₃ N ₃ OS	323	96	62	0.66	60.28 (59.60)	4.89 4.67	23.55 23.45)
5f	C ₁₆ H ₁₅ N ₅ S ₂ O ₂	373	103	92	0.54	58.51	5.40	20.47
5g	C ₁₄ H ₂₁ N ₆ OS	312	112	68	0.63	61.32 (61.12)	6.11 6.06	22.342 2.30)
5h	C ₁₄ H ₁₄ N ₆ O ₂ S ₂	362	122	80	0.66	52.41 (52.30)	4.89 4.76	27.16 27.10)

The combustion analysis of compounds synthesized is within the limits of permissible errors. (± 0.4)

compounds were tested *in-vitro* for their antibacterial activity against two microorganisms *viz.* *Escherichia coli* (NCTC 10418), and *Staphylococcus aureus* (NCTC 6571) which are pathogenic to human beings. The anti-fungal screening was carried out by cup-

plate agar diffusion method using nutrient agar. Inoculation of the test organisms *Aspergillus niger* (NCIM 596) and *Candida albicans* (NCIM 3102) fungal cultures were made in the Sabouraud-Dextrose agar and then incubated at 37°C for 18-24 hr.

Table II — Antibacterial activities of the synthesized compounds

Compd	Zone of inhibition at 200 µg/mL (in mm)			
	<i>E. coli</i>	<i>S. aureus</i>	<i>A. niger</i>	<i>C. albicans</i>
5a	18	17	19	18
5b	22	21	23	22
5c	19	19	19	20
5d	21	22	23	23
5e	18	17	16	18
5f	23	23	22	23
5g	20	20	21	23
5h	24	25	24	23
Norfloxacin	25	25	--	--
Griseofulvin	--	--	24	24

Compounds **5b**, **5d**, **5f**, **5g**, **5h** have shown promising antibacterial and antifungal activities. Norfloxacin and Griseofulvin were used as standard drugs

Table III — Anti-tubercular activity of the synthesized compounds

Compd	Concentration (µg/mL)		
	25	50	100
5a	R	S	S
5b	R	R	R
5c	R	S	S
5d	R	R	R
5e	S	S	S
5f	R	R	R
5g	S	S	S
5h	R	R	R
Streptomycin	S	S	S

R- Resistant S- Sensitive

Compounds **5e** and **5g** have shown significant antitubercular activity at all concentrations. H₃₇ Rv strain was used as standard tubercular organism. Streptomycin was used as standard drug.

Standard drugs Norfloxacin and Griseofulvin were used. The concentration was 200 µg/mL (**Table II**).

Anti-tubercular activity⁷

The antitubercular screening was carried out by Middlebrook 7H9 agar medium against H₃₇Rv strain. Middlebrook 7H9 agar medium contains different derivatives, standard drug as well as control. Middlebrook 7H9 agar medium was inoculated with *Mycobacterium tuberculosis* H37Rv strain. The inoculated bottles were incubated at 37°C for 4 weeks. At the end of 4 weeks they were checked for growth (**Table III**).

Anti-inflammatory activity⁸

Acute anti-inflammatory method: Carrageenan induced rat hind paw edema was produced using type

IV Lambda Carrageenan from Sigma Laboratories. Foot volumes were measured in a plethysmograph by water displacement. The instrument was calibrated before performing the experiment using standard calibrated probe number and standard drug Diclofenac Sodium (**Table IV**).

Experimental Section

Melting points were determined by open capillary method and are uncorrected. Homogeneity of the compounds was checked on silica gel TLC plates. IR spectra were recorded on Thermo Nicole IR 200 spectrophotometer using KBr disc method. ¹H NMR spectra were recorded on Bruker AMX-400 instrument with CDCl₃ as solvent and TMS as internal standard. Combustion analyses were found to be within the limits of permissible errors (**Table I**).

Table IV — Anti-inflammatory activity of synthesized compound

Compd	Mean paw oedema volume \pm SE					% inhibition at 4 th hr
	0 hr	1 hr	2 hr	3 hr	4 hr	
Ct	0.975 \pm 0.025	1.475 \pm 0.025	1.650 \pm 0.028	1.775 \pm 0.025	1.842 \pm 0.012	
Std	0.975 \pm 0.025	1.225 \pm 0.025**	1.325 \pm 0.025**	1.350 \pm 0.028**	1.275 \pm 0.025**	44.47
5a	0.975 \pm 0.025	1.400 \pm 0.041	1.490 \pm 0.025*	1.420 \pm 0.025**	1.364 \pm 0.028**	35.04
5b	1.000 \pm 0.021	1.350 \pm 0.028	1.425 \pm 0.045**	1.500 \pm 0.040**	1.425 \pm 0.047**	40.26
5c	0.975 \pm 0.025	1.350 \pm 0.028	1.500 \pm 0.040*	1.600 \pm 0.0**	1.370 \pm 0.025*	34.45
5d	1.060 \pm 0.0	1.375 \pm 0.025	1.435 \pm 0.028**	1.440 \pm 0.025**	1.320 \pm 0.040**	39.54

One way ANOVA followed by Dunnett's 't' test **P<0.01
Compounds **5b** and **5d** have shown significant anti-inflammatory activity. Diclofenac sodium was used as a standard drug.

General method for synthesis of ester, 1

A mixture of 0.01 mole of acid, 10 mL of absolute ethanol and 2 mL of concentrated sulphuric acid was refluxed for 4 hr. Work-up was carried out as per reported procedures⁹.

General method for synthesis of acid hydrazide, 2

A mixture of 0.01 mole of ester and 0.2 moles (10 mL) of hydrazine hydrate were refluxed in 50 mL of 95% ethanol for 2 hr. The resultant mixture was concentrated, cooled and poured into crushed ice. The solid mass thus separated out was filtered, dried and purified by recrystallization from ethanol⁹.

General method for synthesis of potassium salt of dithiocarbazinate, 3

Potassium hydroxide (0.01 mole) was dissolved in absolute ethanol (75 mL). To the above solution, acid hydrazide **2** (0.01 mole) was added with stirring and cooling in ice. To this, carbon disulphide (10 mL) was added in small portions. The reaction mixture was refluxed for 4-6 hr. The potassium dithiocarbazinate separated was filtered, washed several times with ether and dried in vacuum. The dithiocarbazines were obtained in quantitative yield. As most of the potassium salts of dithiocarbazines were moisture sensitive, they were employed directly for the preparation of aminomercapto triazoles without further purification^{10,11}.

General method for synthesis of 5-mercepto-1,2,4-triazole derivatives, 4

Aqueous solution of 10% NaOH was added in 0.01 mole of primary amines (Isoniazid, sulphanilamide) and the reaction mixture was refluxed for 2 hr. The resulting solution was treated with charcoal, cooled

and filtered. The filtrate was acidified with 10% HCl to adjust the pH between 5-6. The solid mass was precipitated, filtered, washed with ice cold water and purified by recrystallization from ethanol¹². The melting point and percentage yield are reported in **Table I**.

Spectral data

5a: IR (KBr): 3110 (Ar-CH str), 2835 (CH₂ str), 1693 (C=O str), 2500 (SH str), 3540 (NH str), 1550 (C=N str), 367 (C-N str), 678 cm⁻¹ (C-Cl str); ¹H NMR: δ 3.0 (s, 1H, CH₂), 9.2 (s, 1H, NH), 4.0 (s, 2H, NH₂), 2.8 (s, 1H, SH), 7.0-8.0 (d, 4H, pyridyl), 6.2-6.8 (m, 7H, phenyl).

5b: IR (KBr): 3010 (Ar-CH str), 2845 (CH₂ str), 2500 (SH str), 3520 (NH str), 1550 (C=N str), 1300 (C-N str), 678 cm⁻¹ (C-Cl str); ¹H NMR: δ 2.0 (s, 2H, CH₂), 3.0 (s, 1H, SH), 6.2-7.8 (m, 11H, ArH), 3.4 (s, 1H, NH), 3.6-4.0 (s, 2H, NH₂).

5c: IR (KBr): 3120 (ArCH str), 2835 (CH₂ str), 1698 (C=O str), 2500 (SH str), 3545 (NH str), 1550 cm⁻¹ (C=N str).

5d: IR (KBr): 3108 (Ar-CH str), 2840 (CH₂ str), 1695 (C=O str), 2500 (SH str), 3450 (NH str), 1550 cm⁻¹ (NH str).

5e: IR (KBr): 3085 (CH=CH str), 1690 (C=O str), 2500 (SH str), 3539 (NH str), 1550 (C=N str), 1352 cm⁻¹ (C-N str).

5f: IR (KBr): 3030 (CH=CH str), 1698 (C=O str), 2500 (SH str), 3530 (NH str), 1550 (C=N str), 1354 cm⁻¹ (C-N str).

5g: IR (KBr): 3109 (ArCH str), 1689 (C=O str), 2500 (SH str), 3542 (NH str), 1550 (C=N str), 1359 cm⁻¹ (C-N str); ¹H NMR: δ 3.0 (s, 1H, SH), 8.8 (d, 4H, pyridinyl), 7.2-7.4 (m, 4H, phenyl), 4.0 (s, 2H, NH₂), 9.2 (s, 1H, NH).

5h: IR (KBr): 3106 (Ar-CH str), 1694 (C=O str), 2500 (SH str), 3540 (NH str), 1550 (C=N str), 1345 cm^{-1} (C-N str).

Acknowledgement

The authors wish to express their sincere thanks to Hon. Radhakrishna Vikhe Patil, Minister for Agricultural and Marketing Govt. of Maharashtra for his constant encouragement and support, and Shri. Adv. Rajendra Vikhe Patil, Director, Pravara Rural Education Society, Loni. Authors are also thankful to Alkem Laboratories Ltd. for providing free gift sample of Diclofenac sodium.

References

- 1 Patel R J, Patel G C, Patel M M & Patel N J, *Indian J Pharm Educ Res*, 41(2), **2007**, 95.
- 2 John H K & John M B, *Wilson and Gisvold's Text Book of Organic Medicinal and Pharmaceutical Chemistry*, 11th Edn, (Lippincott Williams and Wilkins, Philadelphia), **2004**, pp.1-4.
- 3 Mali R K, Somani R R & Toraska M P, *Chemtech*, 1(2), **2009**, 168.
- 4 Gilchrist T L, *Heterocycl Chem*, 3rd Edn, **1997**, p.288.
- 5 Bauer R W, Kirby M D K, Sherris J C & Turck M, *American J Clin Pathol*, 45, **1966**, 493.
- 6 Barry A L, *The Antimicrobial Susceptibility Test: Principle and Practices* (Leu and Febiger, Philadelphia, Pa, USA), **1976**, p.180; *Biol Abstr*, 64, **1976**, 257.
- 7 Koneman E W, Allen S D, Janda M W & Washington C W, *Textbook of Diagnostic Microbiology*, 5th Edn (J B Lippincott Company Pvt Ltd, Philadelphia), **1997**, p.935.
- 8 Winter C A, Risely G A & Nuss W, *Proc Soc Exp Biol Med*, 3, **1962**, 544.
- 9 Furniss B S, Hannaford A J, Smith P W J & Patchel A R, *Vogel's Text Book of Practical Organic Chemistry*, 5th Edn (Pearson Education Pvt Ltd, Singapore), **1996**, p.1269.
- 10 Dubey A K & Sangwan N K, *Indian J Heterocycl Chem*, 3, **1994**, 277.
- 11 Talwar M B, Laddi U V, Bennur R S & Bennur S C, *Indian J Heterocycl Chem*, 4, **1994**, 111.
- 12 Sayed R E, *Indian J Chem*, 45B, **2006**, 738.